Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

Merck Announces Third Round of 340B Refunds for 2019 Drug Purchases

In Federal, Pharma Industry, RegulatorySeptember 22, 2022150 Views

Drug manufacturer Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

The latest round covers 15 NDCs sold during Q3 2019. The previously announced refunds were for sales during Q1 2019 and Q2 2019. Merck said its recalculated 340B ceiling prices “are the result of revised pricing data that were submitted to the Centers for Medicare & Medicaid Services.” The U.S. Health Resources and Service Administration (HRSA) posted Merck’s notice dated Aug. 19 on its website on Tuesday.

Drug manufacturer Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Merck Announces Third Round of 340B Refunds for 2019 Drug Purchases

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga